BTG plc, a specialist healthcare company, engages in developing and commercializing products targeting critical care, cancer, and other disorders. The company markets and sells specialty pharmaceuticals, including CroFab, a snake bite antivenom to treat envenomation from North American pit viper snakes; DigiFab, an antidote to treat patients with life-threatening toxicity resulting from treatment with digoxin; and Voraxaze for the treatment of life-threatening toxicity due to renal impairment resulting from treatment with high-dose methotrexate. It also offers a range of interventional oncology products comprising Bead Block, LC Bead, and DC Bead used to treat patients with hypervascularised tumours and arteriovenous malformations; and brachytherapy products, primarily implantable seeds used to deliver low-dose radiation to localised prostate tumours. The company’s products in development stage include Varisolve (PEM), a Phase III non-surgical product for the treatment of varicose veins; PARAGON Bead that is in Phase II clinical trial to treat metastatic colorectal cancer; and PRECISION Bead, a Phase II clinical trial product for the treatment of primary liver cancer. Its development products also comprise Alemtuzumab, a Phase III clinical trial product used in the treatment of relapsingremitting multiple sclerosis; Abiraterone acetate, a Phase II clinical product for the treatment of advanced prostate cancer; and AZD9773, a Phase IIb clinical stage product used in treating severe sepsis and/or septic shock. The company’s partnered products include Campath, an anti-lymphocyte antibody for the treatment of B-cell chronic lymphocytic leukaemia; MRC Humanisation IP, an antibody humanisation technology for various indications; two-part hip cup, a prosthetic hip joint replacement to avoid dislocation; and Zytiga for the treatment of men with metastatic castration-resistant prostate cancer. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.

Key Statistics